Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

SHA:600211 Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 12, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	11,871	11,906	12,099	8,906	12,982	16,681
Market Cap Growth	12.00%	-1.59%	35.86%	-31.40%	-22.18%	194.44%
Enterprise Value	9,297	9,880	10,369	7,662	12,467	16,027
Last Close Price	36.83	35.96	34.99	24.84	35.89	45.63
PE Ratio	11.77	11.33	15.11	24.08	62.13	39.90
Forward PE	-	26.48	26.48	26.48	26.48	26.48
PS Ratio	4.22	4.24	3.86	3.49	6.07	12.15
PB Ratio	2.87	3.01	3.59	2.94	4.91	6.45
P/TBV Ratio	3.03	3.20	3.86	3.44	5.88	10.27
P/FCF Ratio	14.35	12.44	11.62	12.11	-	80.63
P/OCF Ratio	13.67	11.97	11.38	10.64	35.42	38.96
EV/Sales Ratio	3.30	3.52	3.31	3.00	5.83	11.67
EV/EBITDA Ratio	10.38	10.21	9.37	10.12	19.06	33.05
EV/EBIT Ratio	11.35	11.06	9.98	11.13	21.77	39.35
EV/FCF Ratio	11.23	10.32	9.95	10.42	-	77.47
Debt / Equity Ratio	0.13	0.07	0.15	0.16	0.20	0.00
Debt / EBITDA Ratio	0.58	0.28	0.45	0.64	0.82	0.02
Debt / FCF Ratio	0.63	0.29	0.48	0.66	-	0.05
Asset Turnover	0.55	0.60	0.72	0.65	0.63	0.48
Inventory Turnover	1.26	1.32	1.50	1.73	2.17	2.69
Quick Ratio	3.66	4.40	2.74	2.51	1.76	3.82
Current Ratio	3.86	4.66	2.87	2.64	1.97	4.06
Return on Equity (ROE)	25.86%	28.86%	25.30%	13.23%	8.14%	16.71%
Return on Assets (ROA)	9.93%	11.96%	14.95%	10.89%	10.61%	8.91%
Return on Capital (ROIC)	11.24%	13.79%	17.56%	12.84%	12.38%	10.09%
Return on Capital Employed (ROCE)	19.60%	22.40%	30.50%	22.40%	21.30%	15.60%
Earnings Yield	8.49%	8.83%	6.62%	4.15%	1.61%	2.51%
FCF Yield	6.97%	8.04%	8.61%	8.26%	-0.46%	1.24%
Dividend Yield	5.15%	5.44%	4.26%	2.31%	0.72%	0.86%
Payout Ratio	57.33%	47.03%	61.74%	26.55%	63.41%	45.16%
Buyback Yield / Dilution	0.27%	0.14%	-0.09%	0.21%	-0.53%	0.98%
Total Shareholder Return	5.42%	5.59%	4.17%	2.52%	0.19%	1.84%

Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.